These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 31015264)

  • 1. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
    Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
    BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
    Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
    Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients.
    Romano LGR; Schütte LM; van Hest RM; Meijer K; Laros-van Gorkom BAP; Nieuwenhuizen L; Eikenboom J; Heubel-Moenen FCJI; Uitslager N; Coppens M; Fijnvandraat K; Driessens MHE; Polinder S; Cnossen MH; Leebeek FWG; Mathôt RAA; Kruip MJHA;
    Haemophilia; 2024 Mar; 30(2):355-366. PubMed ID: 38343113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
    Heijdra JM; Al Arashi W; de Jager NCB; Cloesmeijer ME; Bukkems LH; Zwaan CM; Leebeek FWG; Mathôt RAA; Cnossen MH;
    BMJ Open; 2022 Feb; 12(2):e049493. PubMed ID: 35168962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.
    van Moort I; Preijers T; Bukkems LH; Hazendonk HCAM; van der Bom JG; Laros-van Gorkom BAP; Beckers EAM; Nieuwenhuizen L; van der Meer FJM; Ypma P; Coppens M; Fijnvandraat K; Schutgens REG; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH;
    Lancet Haematol; 2021 Jul; 8(7):e492-e502. PubMed ID: 34171280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC; Lock J; Mathôt RA; Meijer K; Peters M; Laros-van Gorkom BA; van der Meer FJ; Driessens MH; Leebeek FW; Fijnvandraat K; Cnossen MH
    J Thromb Haemost; 2016 Mar; 14(3):468-78. PubMed ID: 26714028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.
    Schütte LM; van Hest RM; Stoof SCM; Leebeek FWG; Cnossen MH; Kruip MJHA; Mathôt RAA
    Thromb Haemost; 2018 Apr; 118(4):621-629. PubMed ID: 29458233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial.
    Mansouritorghabeh H; Shirdel A
    J Thromb Haemost; 2016 Feb; 14(2):336-9. PubMed ID: 26599105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmopressin in haemophilia: The need for a standardised clinical response and individualised test regimen.
    Stoof SCM; Schütte LM; Leebeek FWG; Cnossen MH; Kruip MJHA
    Haemophilia; 2017 Nov; 23(6):861-867. PubMed ID: 28636264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?
    Schütte LM; Hodes LS; van Moort I; Stoof SCM; Leebeek FWG; Cnossen MH; de Maat MPM; Kruip MJHA
    Haemophilia; 2020 Sep; 26(5):916-922. PubMed ID: 32713129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target.
    Schütte LM; de Rooij N; Hazendonk HCAM; Mathôt RAA; van Hest RM; Leebeek FWG; Cnossen MH; Kruip MJHA
    Haemophilia; 2019 Nov; 25(6):960-968. PubMed ID: 31487098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis.
    Arshad F; Stoof SC; Leebeek FW; Ruitenbeek K; Adelmeijer J; Blokzijl H; van den Berg AP; Porte RJ; Kruip MJ; Lisman T
    Liver Int; 2015 Jul; 35(7):1809-15. PubMed ID: 25522671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.
    van Moort I; Bukkems LH; Heijdra JM; Schutgens REG; Laros-van Gorkom BAP; Nieuwenhuizen L; van der Meer FJM; Fijnvandraat K; Ypma P; de Maat MPM; Leebeek FWG; Meijer K; Eikenboom J; Mathôt RAA; Cnossen MH;
    Thromb Haemost; 2020 Jul; 120(7):1056-1065. PubMed ID: 32480417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmopressin in non-severe haemophilia A: Test-response and clinical outcomes in a single Canadian centre review.
    Hews-Girard J; Rydz N; Lee A; Goodyear MD; Poon MC
    Haemophilia; 2018 Sep; 24(5):720-725. PubMed ID: 30004154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
    Delavenne X; Dargaud Y; Ollier E; Négrier C
    Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
    Preijers T; Schütte LM; Kruip MJHA; Cnossen MH; Leebeek FWG; van Hest RM; Mathôt RAA
    Ther Drug Monit; 2019 Apr; 41(2):192-212. PubMed ID: 30883513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.